Menu
Back to Journals » Drug Design, Development and Therapy » Volume 9
A new recombinant factor VIII: from genetics to clinical use
Authors Kannicht C, Kohla G, Tiemeyer M, Walter O, Sandberg H
Received 31 March 2015
Accepted for publication 31 March 2015
Published 23 July 2015 Volume 2015:9 Pages 3817—3819
DOI https://doi.org/10.2147/DDDT.S85608
Checked for plagiarism Yes
Editor who approved publication: Professor Shu-Feng Zhou
Christoph Kannicht,1 Guido Kohla,1 Maya Tiemeyer,2 Olaf Walter,3 Helena Sandberg4
1Octapharma Biopharmaceuticals GmbH, Molecular Biochemistry, Berlin, Germany; 2Octapharma Biopharmaceuticals GmbH, Heidelberg, Germany; 3Octapharma AG, Lachen, Switzerland; 4CoaBio AB, Bromma, Sweden
The December 2014 issue of Drug Design, Development and Therapy included a review article by Santagostino entitled “A new recombinant factor VIII: from genetics to clinical use”.1 The article provided a timely review of recent advances and developments in the treatment of hemophilia A with recombinant factor VIII (rFVIII).1 However, when reviewing licensed rFVIII products, Santagostino1 did not include Human-cl rhFVIII (simoctocog alfa, Nuwiq®).2–4 Nuwiq® is a new-generation rFVIII protein produced in HEK 293 F cells that was approved by the European Medicines Agency in July 2014 for the prevention and treatment of bleeds in hemophilia A patients of all ages.5
Read the original article
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.